Advancing Regenerative Immunology in Pulmonary Medicine
Breathe Biologics, Inc. is a clinical-stage pulmonary biotechnology company focused on the development of regenerative cellular therapies for serious inflammatory and degenerative respiratory diseases.
Focused on Severe Pulmonary Disease
Breathe Biologics is developing JadiCell™, an investigational allogeneic mesenchymal cell platform derived from the subepithelial layer of human umbilical cord tissue.
A pulmonary-focused biotechnology company built around regenerative immunology.
The company's development strategy is centered on diseases in which severe inflammation, immune dysregulation, endothelial injury, epithelial damage, and maladaptive tissue repair contribute to respiratory failure or progressive loss of pulmonary function.
Translating Cellular Biology Into Rigorous Clinical Development
Breathe Biologics is focused on building a development program that integrates clinical evidence, translational medicine, manufacturing science, and pulmonary disease biology.
- Severe inflammatory pulmonary disease
- Regenerative immunology
- Translational biomarker research
- Allogeneic cell-therapy manufacturing
- Evidence-driven clinical development
Pursuing New Approaches to Pulmonary Injury and Repair
Our mission is to advance the scientific and clinical development of regenerative cellular therapies that may address important biological processes underlying severe pulmonary disease.
Science First
Ground development decisions in pulmonary biology, published evidence, translational research, and appropriately controlled clinical investigation.
Clinically Meaningful Development
Focus clinical programs on serious diseases, meaningful endpoints, patient outcomes, and questions that can be evaluated through rigorous study.
Responsible Scientific Communication
Clearly distinguish published evidence, class-level evidence, mechanistic rationale, and investigational hypotheses in scientific communications.
JadiCell™
JadiCell™ is a patented, investigational allogeneic mesenchymal cell platform derived from a distinct anatomical region of umbilical cord tissue using proprietary isolation and manufacturing methods.
A Living Cellular Therapy Platform
Unlike a conventional pharmacologic agent directed at a single molecular target, mesenchymal stromal cells may respond dynamically to the biological environment through paracrine and immunomodulatory signaling.
Investigational Therapy: JadiCell™ has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for the treatment, prevention, diagnosis, or cure of any disease. Safety and efficacy have not been established for any indication.
Connecting Biology, Biomarkers and Clinical Outcomes
Breathe Biologics approaches development as an integrated scientific process connecting disease biology with translational evidence, manufacturing quality, clinical investigation, and patient outcomes.
Built for Scientific, Clinical and Strategic Engagement
Breathe Biologics seeks productive scientific dialogue across the pulmonary research, clinical-development, biotechnology, investment, and non-dilutive funding communities.
Pulmonary Researchers & Physicians
Scientific exchange around pulmonary disease biology, clinical research, translational medicine, and emerging regenerative approaches.
Pharmaceutical & Biotechnology Leaders
Engagement with Business Development, Medical Affairs, clinical-development, regulatory, and advanced-therapy teams.
Investors & Funding Stakeholders
Strategic dialogue with life-science investors and appropriate government or non-dilutive funding stakeholders evaluating pulmonary biotechnology and regenerative-medicine programs.
Leadership & Scientific Expertise
Breathe Biologics brings together leadership experience spanning biotechnology, clinical medicine, immunology, drug development, regulatory strategy, commercialization, intellectual property, legal counsel, and corporate development.
Ed Johnson
Mr. Johnson is a seasoned biotech executive and company builder with a track record of leading organizations at the intersection of science, regulation, and commercialization. He has served in multiple C-suite roles, including Chief Executive Officer, Chief Operating Officer, and Chief Marketing Officer, guiding companies from early development through global market engagement.
In 2020, Mr. Johnson founded and led iOneBioUSA Molecular COVID-19 Technologies, where he worked directly with FDA research and regulatory frameworks while coordinating multinational collaborations with medical laboratories, hospitals, and researchers across North America, Europe, the Middle East, Africa, and Asia.
Previously, Mr. Johnson held leadership roles at Bristol Myers Squibb, contributing to the launch of five branded pharmaceutical products across multiple therapeutic areas. He has also advised life-sciences, medical-device, and pharmaceutical companies on commercialization strategy, corporate development, and investor positioning, and most recently served as an independent director of a publicly traded SPAC involved in the acquisition of a next-generation medical-device company.
James Veltmeyer, M.D.
Dr. Veltmeyer is a board-certified family physician in La Mesa, California. A graduate of UC San Diego and Ross University School of Medicine, he completed his residency through the UC San Francisco system, where he became Chief of Family Medicine Residency and oversaw 36 physicians.
A member of the San Diego Critical Care Medical Group, Dr. Veltmeyer has been recognized by colleagues in the San Diego County Medical Society as a Physician of Exceptional Excellence. He currently serves as Chief of the Department of Family Medicine at Sharp Grossmont Hospital, providing senior leadership to more than 200 physicians.
Feng Lin, M.D., Ph.D.
Dr. Lin has experience in drug development across immunology and immuno-oncology. At Inovio Pharmaceuticals, he worked on technologies for gene delivery and therapeutic DNA vaccines against cancer and infectious diseases in both research and clinical settings.
Dr. Lin subsequently served as Director of Chinese Operations for MediStem Inc., which was acquired by Intrexon in 2014. He also serves as Chief Scientific Officer of Therapeutic Solutions International, Inc.
He received postdoctoral training at Sanford-Burnham Medical Research Institute and earned his M.D. and Ph.D. from Xiangya Medical School of Central South University in China. He has authored more than 20 peer-reviewed scientific publications and holds several patents.
Timothy G. Dixon
Mr. Dixon also serves as Chief Executive Officer, President, and Chairman of Therapeutic Solutions International, Inc., and holds executive and chairman roles across several TSOI subsidiaries.
He previously served as Chief Executive Officer of Breathe Biologics, Inc. and Chairman of Campbell Neurosciences, Inc. Mr. Dixon has experience with corporate compliance matters involving the U.S. Food and Drug Administration and international regulatory bodies.
Mr. Dixon is inventor or co-inventor of more than 75 patents and patents pending.
Hugh D. Kelso III, Esq.
Mr. Kelso graduated from the Thomas Jefferson School of Law in December 1991 and is currently active with the California Bar. With more than three decades of legal and business experience, including corporate governance, securities and transactional law, entity formation, and capitalization, Mr. Kelso has provided legal advice to both for-profit and nonprofit corporations and entities.
His experience includes advising organizations on governance issues, changes in state law, legal compliance, and company and board fiduciary duties. He currently serves as CEO and a member of the Board of Directors of Predictive BioCompounds, Inc., a Wyoming corporation.
Mr. Kelso serves as counsel for Breathe Biologics, Inc., a Delaware corporation; Secretary and director for Campbell Neurosciences, Inc., a Delaware corporation; and corporate securities counsel for Therapeutic Solutions International, Inc., a Nevada corporation.
Since January 2010, Mr. Kelso has served on the Board of Directors of JetMethods, Inc., a privately held Carlsbad, California provider of air charter services. Since May 2016, he has also served on the Board of Directors of AP2020.org, Inc., a Nevada nonprofit serving at-risk and homeless youth, and HWOP.Org, a California nonprofit focused on rehabilitation within California prison populations.
Breathe Biologics, Inc.
A clinical-stage biotechnology company focused on investigational regenerative cellular therapies and pulmonary clinical development.
Pulmonary biotechnology and regenerative medicine.
Investigational allogeneic mesenchymal cell platform.
Scientific, corporate, Medical Affairs, and partnering information.
Scientific & Strategic Engagement
We welcome appropriate inquiries from pulmonary researchers, healthcare professionals, biotechnology and pharmaceutical organizations, research institutions, investors, funding stakeholders, and potential strategic partners.